The Thriving Biopharma Business

How to Unlock Value and Drive Success in Biotech and Pharma
1. Auflage 2025
ISBN: 978-1-032-98312-7
Verlag: Taylor & Francis Ltd

Buch, Englisch, 444 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 453 g

In today’s fiercely innovative and complex biopharmaceutical industry, successfully managing a pharmaceutical or biotech company from concept to patients requires exceptional strategic, leadership, and managerial abilities. This book is a definitive reference that uniquely integrates critical business, strategy, finance, M&A, regulatory, and intellectual property concepts.

Bringing new therapies to market is both a sought-after experience and a distinguished accomplishment. A biopharma leadership team that is able to master the critical levers covered in this book will drive unparalleled value creation through tremendous competitive advantage in the industry. Chapter by chapter, you'll delve into innovation, valuation, intellectual property, strategy, financing, pitching, transactions, contracts, and regulatory affairs. Through numerous case examples and concepts, you’ll learn practical avenues to avoid pitfalls, drive value creation, and navigate the intricate world of the biopharma industry.

This book equips decision-makers, founders, investors, and industry professionals with frameworks, illustrations, and actionable ideas, enabling them to tackle the strategic and managerial challenges inherent in the evolution of a biopharma company. Elevate your strategic decisions, unlock new opportunities, and lead your company to success with this indispensable resource.

Zielgruppe

Adult education, Postgraduate, and Professional Practice & Development

Autoren/Hrsg.

Eudaric, Alain

Pellegrin, Jean-Noel

Pellegrin, Jean-Noël

Fachgebiete

• Wirtschaftswissenschaften Volkswirtschaftslehre Wirtschaftspolitik, politische Ökonomie
• Wirtschaftswissenschaften Betriebswirtschaft Management Unternehmensorganisation & Entwicklungsstrategien
• Sozialwissenschaften Politikwissenschaft Regierungspolitik Wirtschafts- und Finanzpolitik
• Wirtschaftswissenschaften Betriebswirtschaft Management Strategisches Management
• Wirtschaftswissenschaften Wirtschaftssektoren & Branchen Fertigungsindustrie Pharmaindustrie
• Wirtschaftswissenschaften Finanzsektor & Finanzdienstleistungen Finanzsektor & Finanzdienstleistungen: Allgemeines
• Wirtschaftswissenschaften Betriebswirtschaft Management Unternehmensgründung
• Wirtschaftswissenschaften Betriebswirtschaft Management Unternehmensführung

Inhaltsverzeichnis

Preface

Acknowledgments

Chapter 1 Setting the Stage for Biopharma Innovation

Chapter 2 The Basic Valuation Toolkit

Chapter 3 The Rigors and Importance of Intellectual Property

Chapter 4 Strategy for Biopharma Companies

Chapter 5 Company Financing

Chapter 6 Pitching Your Company

Chapter 7 Understanding the Art of the Deal in Biopharma

Chapter 8 Contractual Considerations for Biopharma Deals

Chapter 9 Essential Regulatory Notions

Index

Über Autor(innen)

Alain Eudaric brings over 30 years of global expertise in biopharma, life sciences, and consulting, specializing in strategy, M&A, alliances, and innovation-led growth. He has held leadership roles at Kearney, Thermo Fisher Scientific, and Parexel International, driving transformative programs and business success. As President of Idea Pathways, Alain focuses on driving operational excellence and fostering innovative growth strategies for the biopharma industry. He is an alum from Harvard Medical School, Johns Hopkins University, MIT, Purdue University, and Ecole Centrale de Lille with advanced degrees in Biotech, Business, Science, and Engineering.

Jean-Noël Pellegrin has over 15 years of expertise in M&A and business development, with a proven track record of contributing to several hundred successful transactions. He began his career at EY before most recently joining Sanofi, where he has spent the last 20 years in France and the United States. His 30 years of combined experience across global public company financa, audit, accounting, and strategic transactions make him a trusted expert in valuing life sciences assets and structuring complex deals. He is an alum of Babson College and Sciences Po, with advanced degrees in Business and Finance.